Considering the elevated GITR expression detected in atherosclerosis patients, coupled with the protective effects of GITR blockade against AS progression, GITR stands out as a promising diagnostic biomarker and therapeutic target for future research. This evidence concerns the gene TNFRSF18 and atherosclerosis.